The effect of CH-123, a new antiarteriosclerotic pyrido-1,2a-pyramide derivate was checked in experimental atherosclerosis of rabbits. Cholesterol deposition was found to continue after 4-week cholesterol feeding even after the cholesterol level had returned to normal. This allowed to study the action of drugs in a phase dominated by lipid apposition to the vascular wall. In the experiments, clofibrate was used for reference. As judged by the lipid values in serum and aortic wall, CH-123 reduced substantially the deposition of lipids, mainly of cholesterol, into the aortic wall.